Advances in targeted BRAF and MEK in patients whose melanoma harbor mutations in BRAF and the emergence of T cell checkpoint inhibitors alone and in combination have revolutionized the therapeutic approach to advanced melanoma. The gene discussed is BRAF; the disease is melanoma.